GE CEO to Tout Health-Care Push


Published On: May 7th, 2009

ImmeltNote: This post is updated from its initial form to reflect new information released by GE this morning.

GE CEO Jeff Immelt (pictured) is scheduled to be in Washington this morning, talking up the company’s plan to spend $6 billion over six years in an effort to expand its health-care business.

It’s not entirely clear yet what exactly Immelt will say, nor is it clear whether the money is all new funding or whether it includes existing expenditures, the WSJ reports.

GE has been in the business of selling medical equipment for decades, but may be looking for growth in other health-related areas.

Given that the talk is in DC, and that the stimulus bill includes more than $30 billion in federal incentives for doctors and hospitals to buy electronic health-records systems, it seems reasonable to expect at least some focus on GE’s EHR business.

The Rwandan ambassador is also expected be there, suggesting the presentation will include GE’s work to expand its health-care business in the developing world. And an Intel exec is also supposed to attend; Intel and GE recently announced a collaboration designed to allow doctors to monitor patients at home. Here’s more on that effort.


Read more here: 
GE CEO to Tout Health-Care Push

STOP PANIC ATTACKS - A Natural Technique To Stop Panic Attacks and Anxiety Fast!

Stop Panic Attacks
The technique I teach has been developed by me Joe Barry, a former sufferer of all too frequent panic attacks and GAD. I developed a completely natural approach to eliminating 100% of general anxiety and panic attacks. This may seem very hard to believe for someone who may have had this condition for some time but believe me the new information is now available to be free from anxiety. I will reveal the whole technique to you.

try-now

YouTube Video



Loading...


Did You Know Did you know:


Lung related deaths account for 62.9 per 100,000 people per year

Related Posts

  • J&J Antes Up $1 Billion for Alzheimer’s Push With Elan
    Health-care giant J&J is making a $1 billion bet for a stake in Irish drug maker Elan and will invest an additional $500 million in Elan’s closely watched experimental bapineuzumab that is in late-stage studies to treat Alzheimer’s, the companies announced this morning. With the deal, Elan essentially turns over to J&J the development rights..
  • A.M. Vitals: J&J Latest to See Drug Shortage
    In Short Supply: Johnson & Johnson is experiencing a shortage of its cancer drug Doxil due to production delays at a contract manufacturer, the WSJ reports . The company is advising doctors not to start new patients on the drug and to consult national treatment guidelines for alternatives ..
  • Does Pfizer CEO Regret Sale of Consumer Products to J&J?
    In an interview with the Financial Times , J&J CEO Bill Weldon gets to gloat about running the mother of all diversified health companies at a moment when many big drug makers are looking to diversify. He notes that the pendulum of opinion swings back and forth on the value of diversification: “For years we..
  • HHS Beefs Up Healthcare.gov With Private Plan Data, Denial Rates
    Pricing information covers more than 4,400 private plans from 225 different insurers. ..
  • GSK, J&J, Sanofi on New Alzheimer’s Data Collaborative
    What drug company execs hope to get out of the new collaboration. ..
  • Pfizer Holders Want Say on Exec Pay; J&J Holders, Not So Much
    Both Pfizer and Johnson & Johnson held their annual meetings today, which makes for an interesting study in contrasts. Pfizer shareholders voted to give themselves an “advisory vote” on executive compensation, while J&J shareholders voted down a similar proposal, notes Pete Loftus of Dow Jones Newswires. Both votes were close: 52% in favor at Pfizer, versus..
Leave a comment
Comments are closed.
« Massachusetts Looks to Change the Way Doctors Are Paid Adding Up Obama’s Proposed Increases to FDA Budget »